JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.
International webinar on The Pharmacy Practice: The Global Scenario
RBVRR WOMEN’S COLLEGE OF PHARMACY,Barkatpura, Hyderabad
Feedback form : Dt 08th,April ,2021
Session no:2 Career paths in Pharmacovigilance
* Indicates required question
Email
*
Your email
1.
Name of the participant and Institute
*
Your answer
2. Mark one of recent drug withdrawn from the market because of its Cardiotoxicity
*
Lumiracoxib
Ximelagatran
Trovafloxacin
Rosiglitazone
3.Mark the main lessons from Thalidomide disaster
*
need for government regulation of medicines
need for systems to identify the adverse effects of medicines
Adequately tested before it is brought into the market
All of the above
4.An authorization approval of any drug can be obtained only
*
When the benefits outweight are risks
When risks outweighs benefits
When there is no risks
When there are only benefits
5. Day zero or initial receipt date of ADR is valid when
*
when it has four identifiable factors
when it has atleast one identifiable factors
when it has five identifiable factors
when it has three identifiable factors
6. Serious ADR should be reported with how many number of days
*
15 CALENDER DAYS
10 CALENDER DAYS
90 CALENDER DAYS
100 CALENDER DAYS
7. All adverse drug reactions (ADRs) that are both serious and unexpected of one single case is called
*
Expedite reporting
Periodic reporting
Intensive event report
Signal management study
8. Periodic benefit evaluation report includes
*
World wide reports
Patient exposure
summary tabulations
All of the above
9. Periodic Benefit-Risk Evaluation Report is included in which ICH guidelines
*
E2B
E2A
E2C
E2D
10. Would you like to attend more sessions like this?
*
Yes
No
Submit
Clear form
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google.
Report Abuse
-
Terms of Service
-
Privacy Policy
Forms
